StockWatch
·
Misc Health and Biotechnology Services
Quarterly ResultAug 6, 2026, 04:22 PM

Progyny Q2 Revenue $350.5M, Net Income $28.1M, EPS $0.34

AI Summary

Progyny, Inc. announced strong financial results for the second quarter of 2026, reporting record quarterly revenue, gross profit, and Adjusted EBITDA. Revenue increased 5.3% to $350.5 million, or 11.0% when excluding the impact of a large, non-renewing client from the prior year. Net income rose to $28.1 million, resulting in $0.34 diluted earnings per share, while Adjusted EBITDA grew 7.2% to $62.1 million. The company also repurchased nearly 1.2 million shares for $31.5 million and provided Q3 and full-year 2026 financial guidance.

Key Highlights

  • Q2 2026 Revenue was $350.5 million, a 5.3% increase from Q2 2025.
  • Q2 2026 Net Income reached $28.1 million, up from $17.1 million in Q2 2025.
  • Q2 2026 Diluted EPS was $0.34, compared to $0.19 in Q2 2025.
  • Q2 2026 Adjusted EBITDA increased 7.2% to $62.1 million.
  • Q2 2026 Gross Profit was $89.3 million, a 13% increase from Q2 2025.
  • Nearly 1.2 million shares were repurchased for $31.5 million in Q2 2026.
  • Full Year 2026 Revenue guidance is $1.360 billion to $1.385 billion.
  • Full Year 2026 Adjusted EBITDA guidance is $233.0 million to $240.0 million.